Bayer AG (FRA:BAYA) Other Financing: €-1,697 Mil (TTM As of Mar. 2026)


FRA:BAYA Bayer AG FRA:BAYA
66 GF Score
Price €12.30
GF Value €7.16
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Bayer AG Other Financing?

Bayer AG FRA:BAYA +4.24% 66 Other Financing is €-1,697 Mil as of Mar. 2026. GuruFocus rates FRA:BAYA with a GF Score™ of 66/100 and a GF Value™ of €7.16 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Bayer AG's Other Financing for the three months ended in Mar. 2026 was €-202 Mil.

Bayer AG's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was €-1,697 Mil.

Bayer AG Other Financing Historical Data

* Premium members only.

The historical data trend for Bayer AG's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bayer AG Other Financing Chart

Bayer AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,200.00 -1,251.00 -1,552.00 -2,013.00 -1,698.00

Bayer AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -217.00 -529.00 -358.00 -608.00 -202.00
FRA:BAYA
66GF Score
Bayer AG FRA:BAYA
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bayer AG Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1,697 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €-1,697 Mil mean?
Bayer AG (FRA:BAYA) has a Other Financing of €-1,697 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Bayer AG and its competitors.
Is Bayer AG's Other Financing too high?
Bayer AG's current Other Financing is €-1,697 Mil. Overall, Bayer AG has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's Other Financing compare to LLY and JNJ?
Bayer AG's Other Financing of €-1,697 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Bayer AG and its competitors. Bayer AG's current Other Financing is €-1,697 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (FRA:BAYA) is currently considered Significantly Overvalued. The stock's GF Value™ is €7.16, compared to a current price of €12.30 — trading 71.8% above its estimated fair value. The current Other Financing is €-1,697 Mil. Bayer AG's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Bayer AG (FRA:BAYA), the current Other Financing is €-1,697 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bayer AG (FRA:BAYA) Overvalued in 2026?

Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued. The current stock price of €12.30 is trading 71.8% above its estimated GF Value™ of €7.16. GuruFocus considers Bayer AG to be Significantly Overvalued.

Key valuation signals for FRA:BAYA:

  • Other Financing: €-1,697 Mil
  • GF Value™: €7.16 vs. price of €12.30 (71.8% above fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the FRA:BAYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bayer AG Business Description

Address Kaiser-Wilhelm-Allee 1, Leverkusen, NW, DEU, 51368
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
66GF Score

Get the complete analysis for FRA:BAYA

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.30
Price
€7.16
GF Value